The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

This was the stock's third consecutive day of losses.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Health Care Select Sector SPDR® Fund ETF (NYSEARCA:XLV), which tracks the health care sector, and holds a weightage of 12 ...